Work

Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial

Year: 2025

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)03586-4

Authors: James Hoffman, Naresh Bumma, Joshua Richter, Madhav Dhodapkar, Hans Lee, Attaya Suvannasankha, Jeffrey Zonder, Joseph Maly, Mansi Shah, Rachid Baz, Ka Lung Wu, Timothy Inocencio, Michelle DeVeaux, Karen Rodriguez Lorenc, Glenn Kroog, Kate Knorr, James Harnett, Qiufei Ma, Sundar Jagannath

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414303663

FWCI: 0.644

Cites:

Cited by: 1

Related to: